Skip to main
AYTU

Aytu BioScience (AYTU) Stock Forecast & Price Target

Aytu BioScience (AYTU) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Aytu BioPharma Inc. presents an attractive current valuation, reflecting a positive outlook supported by a net present value (NPV) analysis that indicates significant upside potential from the existing share price. The company is advancing its commercial portfolio, particularly with the upcoming launch of its EXXUA product for treating major depressive disorder, projected for Q4 2025, which is expected to serve as a strong catalyst for the stock's performance. Additionally, clinical trials for EXXUA have shown promising results in improving depression symptoms with a favorable side effect profile, further enhancing the company's market position in specialty pharmaceuticals.

Bears say

Aytu BioPharma reported Q1 results indicating a revenue of $13.9 million, which reflects a decline of 16% year-over-year, despite exceeding internal estimates. The company's stock is perceived as undervalued based on future sales projections, yet this potential is contrasted by a lack of consistent revenue performance, raising concerns about overall financial stability. Additionally, while the market for antidepressant prescriptions shows substantial growth and unmet needs, Aytu BioPharma's product offerings may not adequately capitalize on this opportunity, contributing to a cautious outlook.

Aytu BioScience (AYTU) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Aytu BioScience and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Aytu BioScience (AYTU) Forecast

Analysts have given Aytu BioScience (AYTU) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Aytu BioScience (AYTU) has a Strong Buy consensus rating as of Jan 10, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Aytu BioScience (AYTU)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.